The purpose of this multicenter, double-blind, randomized, parallel-group study was to determine the effect of thirteen 28-day cycles of drospirenone combined with estradiol, compared with estradiol alone, on the endometrium of postmenopausal women.
Postmenopausal women not on hormone therapy but with an intact uterus were enrolled (N = 1,147); 1,142 were evaluated. Participants were randomly assigned to treatment with 1.0 mg of estradiol alone (E2 monotherapy) or 1.0 mg of estradiol plus 0.5, 1.0, 2.0, or 3.0 mg of drospirenone (DRSP/E2). Endometrial biopsies were performed at baseline, at 7 months if indicated, and at study end in the 13th month. Safety was evaluated with peripheral blood samples for hematology, liver and renal function, and lipids, along with vital signs and interval medical evaluations.
When compared with estradiol alone, combinations of drospirenone and estradiol were effective in protecting against endometrial hyperplasia. The probability of hyperplasia was 0.060 (95% CI, 0.043-0.078) for the E2 monotherapy group, 0.007 for the 2-mg DRSP/E2 group, and nonsignificant for the remaining drospirenone/estradiol groups.
Endometrial bleeding decreased in all treatment groups over time. The combination of drospirenone and E2 relieved menopausal symptoms and resulted in improvements in health-related quality-of-life measures. There were no significant adverse events, and effects on triglycerides, total cholesterol, and high-density lipoprotein cholesterol were positive.
The use of drospirenone combined with estradiol provides protection against endometrial hyperplasia, reduces endometrial bleeding with time, and relieves menopausal symptoms. There were no safety issues and blood pressure was reduced in women with hypertension.
Drospirinone at doses of 0.5, 1.0, 2.0, and 3.0 mg combined with 1.0 mg of estradiol effectively inhibited hyperplasia of the endometrium compared with 1.0 mg of estradiol alone, and resulted in minimal vaginal bleeding. Safety and acceptability were confirmed by evaluating participant health related quality of life parameters, serum lipids, apolipoproteins, Lp(a), blood pressure and adverse events.
From the 1CONRAD Clinical Research Center, Norfolk, VA; 2University of South Alabama, OB/GYN Research, Mobile, AL; 3Berlex Laboratories, Montville, NJ; 4DCL Medical Laboratories, Inc, Indianapolis, IN; 5Rush University Medical Center, Chicago, IL; 6Department of Pathology, Stanford University, Stanford, CA.
Received April 15, 2005; revised and accepted June 29, 2005.
Support from Berlex, Inc. (Montville, NJ) is gratefully acknowledged.
Address correspondence to: David F. Archer, MD CONRAD Clinical Research Center, 601 Colley Avenue, Norfolk, VA 23507. E-mail: firstname.lastname@example.org.